Technological products portfolio

Erectile dysfunction (ED) affects approximately 1 in 5 men over the age of 40 and 1 in 2 men over the age of 70. The first-line treatment remains largely the prescription of PDE5 inhibitors (phosphodiesterase type 5 inhibitors: e.g., sildenafil, tadalafil, etc.), but approximately one-third of patients treated do not respond sufficiently. Furthermore, the ineffectiveness of PDE5 inhibitors increases with the presence of comorbidities such as diabetes, a history of prostatectomy, or cardiovascular disease. There is therefore a significant medical need for an effective, safe, and non-restrictive treatment option in cases where PDE5 inhibitors are insufficiently effective or ineffective.

Le projet CBORBIG résout ce problème de reconnaissance en temps réel dans les vidéos.

The GenED project aims to develop a gene therapy vector that allows for the prolonged expression of a transgene capable of inducing its long-term effect. The GenED solution aims to improve acceptability and increase ease of implementation compared to existing second- and third-line treatments in cases where IPDE5s have failed.

This approach will enable long-term expression of a transgene and may be combined with on-demand oral IPDE5 treatment. This combination offers a synergistic effect, as it targets two complementary pathways, thereby significantly increasing treatment efficacy in patients.